Balaji V. Kadri has more than 18 years of formulation and process development experience within the contract research and generic industry. Most recently, he was director of Formulation Development and cGMP manufacturing at QS Pharma, Pennsylvania, with responsibility for formulation development and manufacturing. He was previously senior director/Head of Pharmaceutical Operations at PharmaForm, Texas, where he was responsible for analytical, formulation development, cGMP manufacturing, Quality Control, and Warehouse departments. Prior to that, he headed the Preformulation and Formulation Development group at Xcelience, Florida, for 10 years. He previously worked in formulation development and scale-up manufacturing at Apotex, Ontario, for six years. His broad dosage form experience includes immediate release tablets and capsules, sustained release capsules/tablets/beads, liquid/semi-solid in capsule, gels, paediatric solutions, suspensions, and parenteral. His expertise includes formulation development from preclinical to commercialization, overcoming solubilisation challenges, enhancing bioavailability, taste masking, and development of controlled release dosage forms. He has authored numerous articles, presented many abstracts, is co-inventor of several patents and is a contributor of several excipient monographs in “Handbook of Pharmaceutical Excipients” 7th edition (2012). He is an active member of the American Association of Pharmaceutical Scientists (AAPS), editorial member of Contract Pharma magazine, and a registered life member in the Karnataka State Pharmacy Council in India. He has completed M.Pharm (pharmaceutics) from India, M.Sc (Pharmaceutics) from Canada, and MBA (Management) from USA.